Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GPR27 | Q9NS67 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30451431 | 1.00 | TSHR (0.36) | TSHRDGAT1ALDH1A1MAPTGPR27 | |
| SCHEMBL21513677 | 0.92 | DGAT1 (0.35) | TSHRDGAT1HDAC1HDAC6CYP1A2 | |
| SCHEMBL29876292 | 0.92 | DGAT1 (0.35) | TSHRDGAT1HDAC1HDAC6CYP1A2 | |
| SCHEMBL31726717 | 0.84 | TSHR (0.40) | TSHRALDH1A1MAPTHDAC1HDAC6 | |
| SCHEMBL1721699 | 0.84 | TSHR (0.40) | TSHRALDH1A1MAPTHDAC1HDAC6 | |
| SCHEMBL24816756 | 0.82 | DGAT1 (0.48) | DGAT1ALDH1A1MAPTHDAC1HDAC6 | |
| SCHEMBL2726898 | 0.82 | KDM4E (0.50) | DGAT1ALDH1A1MAPTKDM4EGLA | |
| SCHEMBL30204393 | 0.82 | GPR27 (0.41) | TSHRDGAT1ALDH1A1GPR27MAOB | |
| SCHEMBL4949499 | 0.82 | GPR27 (0.41) | TSHRDGAT1ALDH1A1GPR27MAOB | |
| Hydrochloric Acid SCHEMBL18954184 | 0.81 | KDM4E (0.48) | DGAT1ALDH1A1MAPTKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-2797911-B1 | HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-28 | — | — | EP | disclosed |
| EP-2797911-B1 | HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-28 | — | — | EP | disclosed |
| US-9126986-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-08 | — | — | US | disclosed |
| US-9126986-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-08 | — | — | US | disclosed |
| US-9126986-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-08 | — | — | US | disclosed |
| US-20140357626-A1 | Hetero-Bicyclic Derivatives As HCV Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2014-12-04 | — | — | US | disclosed |
| US-20140357626-A1 | Hetero-Bicyclic Derivatives As HCV Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2014-12-04 | — | — | US | disclosed |
| US-20140357626-A1 | Hetero-Bicyclic Derivatives As HCV Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2014-12-04 | — | — | US | disclosed |
| EP-2797911-A1 | HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS | Janssen R&D Ireland (IE) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013098313-A1 | HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013098313-A1 | HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | TSHR 2377/4885DGAT1 2858/4885ALDH1A1 653/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | TSHR 2377/4885DGAT1 2858/4885ALDH1A1 653/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | TSHR 2377/4885DGAT1 2858/4885ALDH1A1 653/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | TSHR 437/4885DGAT1 4590/4885ALDH1A1 3178/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | TSHR 204/4885DGAT1 2889/4885ALDH1A1 3094/4885 |
| US-20140357626-A1 | Hetero-Bicyclic Derivatives As HCV Inhibitors | HAVCR2, ZC3HAV1, SUB1 | TSHR 4586/4885DGAT1 919/4885ALDH1A1 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.